Article
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket.
Proceedings of the National Academy of Sciences of the United States of America - 25 Oct 2022
Wallon Lauren, Khan Imran, Teng Kai Wen, Koide Akiko, Zuberi Mariyam, Li Jianping, Ketavarapu Gayatri, Traaseth Nathaniel J, O'Bryan John P, Koide Shohei
Abstract excerpt
RAS mutants are major therapeutic targets in oncology with few efficacious direct inhibitors available. The identification of a shallow pocket near the Switch II region on RAS has led to the development of small-molecule drugs that target this site and inhibit KRAS(G12C) and KRAS(G12D). To discover other regions on RAS that may be targeted for inhibition, we have employed small synthetic binding proteins termed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.